Intrinsic radiosensitivity of human cell lines is correlated with radioresponsiveness of human tumors: Analysis of 101 published survival curves

doi:10.1016/0360-3016(85)90223-8

International Journal of Radiation OncologyBiologyPhysics

Volume 11, Issue 9, September 1985, Pages 1699-1707

https://doi.org/10.1016/0360-3016(85)90223-8 Get rights and content

Abstract

One hundred and one published survival curves for 92 human cell lines (including 64 tumor lines) have been analyzed in terms of several parameters that are supposed to characterize cell radiosensitivity. Values for n, D_o, α and β (from the linear quadratic model), $D$ (Mean Inactivation Dose), and survivals at 2 Gy and 8 Gy have been obtained for each curve. It was found that: I. the initial part of the survival curve is specific to the corresponding cell line; II. this initial part is well characterized by the parameters a and $D$ , the values of which can be used to compare intrinsic radiosensitivity among human cell lines; III. human tumor cell line radiosensitivity (expressed in terms of α, $D$ and survival at 2 Gy) reflects the clinical radioresponsiveness of the tumors from which the cell lines are derived. Thus, cells from tumors with low radioresponsiveness (melanomas and glioblastomas) are the less radiosensitive. Furthermore, the range of survival at a dose of 2 Gy is broad enough to account, in large measure, for observed differences in clinical tumor radioresponsiveness.

References (51)

A.S. Bellamy et al.
Studies of variation in inherent sensitivities to radiation, 5-fluorouracil and methotrexate in a series of human and murine tumor cell lines in vitro
Int. J. Radiat. Oncol. Biol. Phys.
(1984)
R.J. Berry et al.
Perturbation in X-ray dose response in vitro with time after plating. A pitfall in the comparison of results obtained by different laboratories using asynchronous cell systems
Exp. Cell Res.
(1966)
B. Drewinko et al.
Radiation response of cultured human carcinoembryonic antigen producing colon adenocarcinoma cells
Int. J. Radiat. Oncol. Biol. Phys.
(1977)
B. Fertil et al.
Inherent cellular radiosensitivity as a basic concept for human tumor radiotherapy
Int. J. Radiat. Oncol. Biol. Phys.
(1981)
P.J. Selby et al.
In vitro cellular radiosensitivity of human malignant melanoma
Int. J Radiat. Oncol. Biol. Phys.
(1982)
A. Szechter et al.
Continuous and fractionated irradiation of mammalian cells in culture. I. The effect of growth rate
Int. J Radiat. Oncol. Biol. Phys.
(1978)
R.R. Weichselbaum et al.
In vitro cellular radiosensitivity of human malignant tumors
Europ. J. Cancer
(1976)
R.R. Weichselbaum et al.
Repair of potentially lethal X ray damage and possible applications to clinical radiotherapy
Int. J. Radiat. Oncol. Biol. Phys.
(1983)
R.R. Weichselbaum et al.
X-ray sensitivity of human tumor cells in vitro
Int. J Radiat. Oncol. Biol. Phys.
(1980)
T. Alper
Cellular Radiobiology
(1979)

C.F. Arlett et al.

Survey of radiosensitivity in a variety of human cell strains

Cancer Res.

(1980)

S.C. Barranco et al.

The radiation response of human malignant melanoma cells grown in vitro

Cancer Res.

(1971)

P.E. Bryant et al.

Changes in sensitivity of the HeLa cells after split dose of X-rays

Int. J. Radiat. Biol.

(1979)

D.N. Carney et al.

In vitro radiation and chemotherapy sensitivity of established cell lines of human small cell lung cancer and its large cell morphological variants

Cancer Res.

(1983)

A. Courdi et al.

Establishments, characterisation and response to cytotoxic and radiation treatment of three human melanoma cell lines

In vitro

(1983)

A. Courdi et al.

In vitro low dose survival of freshly excised human tumour cells (Abstract)

R. Cox et al.

Ataxia telangiectasia. Evaluation of radiosensitivity in cultured skin fibroblasts as a diagnostic test

Arch. Dis. Child.

(1978)

P.J. Deschavanne et al.

Radiosensitivity and repair of radiation damage in human HF19 fibroblasts

Int. J. Radiat. Biol.

(1980)

P.J. Deschavanne et al.

Radiation survival of glutathione deficient human fibroblasts in culture

Brit. J. Radiol.

(1981)

B. Fertil et al.

Mean inactivation dose: a useful concept for intercomparison of human cell survival curves

Radiat. Res.

(1984)

B. Fertil et al.

In vitro radiosensitivity of six human cell lines. A comparative study with different statistical models

Radiat. Res.

(1980)

L.E. Gerweck et al.

Radiation sensitivity of cultured human glioblastoma cells

Radiology

(1977)

E.J. Hall et al.

Dose rate. Its effect on the survival of HeLa cells irradiated with gamma rays

Radiat. Res.

(1964)

A.W. Hamburger et al.

Primary bioassay of human tumor stem cells

Science

(1977)

ICRU

International Commission on Radiation Units and Measurements: Quantitative concepts and dosimetry in radiobiology

ICRU Report

(1979)

Cited by (449)

Radiosensitivity Index is Not Fit to be Used for Dose Adjustments: A Pan-Cancer Analysis
2023, Clinical Oncology
To explore the preclinical and latest clinical evidence of the radiation sensitivity signature termed ‘radiosensitivity index’ (RSI), to assess its suitability as an input into dose-adjustment algorithms.
The original preclinical test-set data from the publication where RSI was derived were collected and reanalysed by comparing the observed versus predicted survival fraction at 2 Gy (SF2). In addition, the predictive capability of RSI was also compared to random guessing. Clinical data were collected from a recently published dataset that included RSI values, overall survival outcomes, radiotherapy dose and tumour site for six cancers (glioma, triple-negative breast, endometrial, melanoma, pancreatic and lung cancer). Cox proportional hazards models were used to assess: (i) does adjusting for RSI elucidate a dose response and (ii) does an interaction between RSI and dose exist with good precision.
Preclinically, RSI showed a negative correlation (Spearman's rho = –0.61) between observed and predicted SF2, which remained negative after removing leukaemia cell lines. Furthermore, random guesses showed better correlation to SF2 than RSI, 98% of the time on the full dataset and 80% after removing leukaemia cell lines. The preclinical data show that RSI does not explain the variance in SF2 better than random guessing. Clinically, a dose response was not seen after adjusting for RSI (hazard ratio = 1.00, 95% confidence interval 0.97–1.04; P = 0.876) and no evidence of an interaction between RSI and dose was found (P = 0.844).
These results suggest that RSI does not explain a sufficient amount of the outcome variance to be used within dose-adjustment algorithms.
Challenges in radiobiology – technology duality as a key for a risk-free α/β ratio
2023, Bulletin du Cancer
Since radiotherapy discovery, prediction of biological response to ionizing radiation remains a major challenge. Indeed, several radiobiological models appeared through radiotherapy history. Nominal single dose so popular in the 1970s, was tragically linked to the dark years in radiobiology by underestimating the late toxicity of the high-dose fractions. The actual prominent linear-quadratic model continues to prove to be an effective tool in radiobiology. Mainly with its pivotal α/β ratio, which gives a reliable estimate of tissues sensitivity to fractions. Despite these arguments, this model experiences limitations with substantial doubts of α/β ratio values. Interestingly, the story of radiobiology since X-ray discovery is truly instructive and teaches modern clinicians to refine fractionation schemes. Many fractionation schemes have been tested with successes or dramas. This review retraces radiobiological models’ history, and confronts these models to new fractionation schemes, drawing a preventive message.
Depuis la découverte de la radiothérapie, la prédiction de la réponse biologique aux rayonnements ionisants reste un défi majeur. En effet, plusieurs modèles radiobiologiques sont apparus au cours de l’histoire de la radiothérapie. La dose unique nominale, si populaire dans les années 1970, a été tragiquement liée aux années noires de la radiobiologie en sous-estimant la toxicité tardive des fractions à fortes doses. Le modèle linéaire-quadratique actuel, très en vue, continue de s’avérer un outil efficace en radiobiologie. Principalement grâce à son rapport α/β, qui donne une estimation fiable de la sensibilité des tissus aux fractions. Malgré ces arguments, ce modèle connaît des limites avec des incertitudes avérées sur les valeurs du rapport α/β. Il est intéressant de noter que l’histoire de la radiobiologie depuis la découverte des rayons X est réellement instructive et apprend aux cliniciens modernes à affiner les schémas de fractionnement. De nombreux schémas de fractionnement ont été testés avec des succès ou des drames. Cette revue retrace l’histoire des modèles radiobiologiques, et confronte ces modèles aux nouveaux schémas de fractionnement, en tirant un message préventif.
Radiation Therapy for Local Cutaneous Melanoma
2021, Clinics in Plastic Surgery
Citation Excerpt :
A clear role of radiation therapy in the treatment of primary melanoma has not been well defined. This is due, in part, to preclinical studies in human cell lines that suggested melanoma was intrinsically radioresistant, or needed a higher dose per fraction radiotherapy to produce a response.2–5 In more modern clinical situations, the paucity of phase III clinical studies characterizing the use of radiation therapy for primary melanoma represents a challenge for oncologists seeking to form treatment plans.
Complementary and Alternative Medicine for the Treatment of Gliomas: Scoping Review of Clinical Studies, Patient Outcomes, and Toxicity Profiles
2021, World Neurosurgery
Complementary and alternative medicine (CAM) are highly used among those diagnosed with glioma. Further research is warranted, however, as it remains important to clearly delineate CAM practices that are unproven, disproven, or promising for future research and implementation.
A systematic review was conducted to identify all articles that investigated the effect of any CAM therapy on survival of patients with newly diagnosed or recurrent glioma.
Eighteen papers and 4 abstracts pertaining to the effects of ketogenic diet (4), antioxidants (3), hyperbaric oxygen (4), cannabinoids (2), carbogen and nicotinamide (3), mistletoe extract (2), hypocupremia and penicillamine (1), and overall CAM use (3) on overall and progression-free survival in patients with low- and high-grade glioma were identified (Levels of Evidence I-IV). Ketogenic diets, hyperbaric oxygen therapy, and cannabinoids appear to be safe and well tolerated by patients; preliminary studies demonstrate tumor response and increased progression-free survival and overall survival when combined with standard of care therapies. Antioxidant usage exhibit mixed results perhaps associated with glioma grade with greater effect on low-grade gliomas; vitamin D intake was associated with prolonged survival. Conversely, carbogen breathing and hypocupremia were found to have no effect on the survival of patients with glioma, with associated significant toxicity. Most modalities under the CAM umbrella have not been appropriately studied and require further investigation.
Despite widespread use, Level I or II evidence for CAM for the treatment of glioma is lacking, representing future research directions to optimally counsel and treat glioma patients.
X-ray on chip: Quantifying therapeutic synergies between radiotherapy and anticancer drugs using soft tissue sarcoma tumor spheroids
2021, Radiotherapy and Oncology
Radioresistance, tumor microenvironment, and normal tissue toxicity from radiation limit the efficacy of radiotherapy in treating cancers. These challenges can be tackled by the discovery of new radiosensitizing and radioprotecting agents aimed at increasing the therapeutic efficacy of radiotherapy. The goal of this work was to develop a miniaturized microfluidic platform for the discovery of drugs that could be used in combination with radiotherapy. The microfluidic system will allow the toxicity testing of cancer spheroids to different combinations of radiotherapy and molecular agents.
An orthovoltage-based technique was used to expose the devices to multiple X-ray radiation doses simultaneously. Radiation dose-dependent DNA double-strand breaks in soft tissue sarcoma (STS) spheroids were quantified using comet assays. Analysis of proliferative death using clonogenic assays was also performed, and synergy between treatments with Talazoparib, Pazopanib, AZD7762, and radiotherapy was quantified using dedicated statistical tests.
The developed microfluidic system with simple magnetic valves was capable of growing 336 homogeneous STS spheroids. The irradiation of the microfluidic system with an orthovoltage-based technique enabled the screening of sixteen drug-radiotherapy combinations with minimal reagent consumption. Using this framework, we predicted a therapeutic synergy between a novel anticancer drug Talazoparib and radiotherapy for STS. No synergy was found between RT and either Pazopanib or AZD7762, as the combinations were found to be additive.
This methodology lays the basis for the systemic search for molecular agent/radiotherapy synergies among preexisting pharmaceutical compounds libraries, in the hope to identify failed drug candidates in monotherapy that, in the presence of radiotherapy, would make it through clinical trials.
Combined BNCT-CIRT treatment planning for glioblastoma using the effect-based optimization
2024, Physics in Medicine and Biology

View all citing articles on Scopus

^☆

This work has been partly presented at the 3rd ESTRO meeting, Jerusalem, September 1984.

This work was supported. in part by the “Ligue Nationale Française Contre le Cancer” (Comité des Hauts-de-Seine) and by the “Comité de Radioprotection de l'Electricité de France”).

View full text

Oncology intelligenceIntrinsic radiosensitivity of human cell lines is correlated with radioresponsiveness of human tumors: Analysis of 101 published survival curves☆

Abstract

Int. J. Radiat. Oncol. Biol. Phys.

Exp. Cell Res.

Int. J. Radiat. Oncol. Biol. Phys.

Int. J. Radiat. Oncol. Biol. Phys.

Int. J Radiat. Oncol. Biol. Phys.

Int. J Radiat. Oncol. Biol. Phys.

Europ. J. Cancer

Int. J. Radiat. Oncol. Biol. Phys.

Int. J Radiat. Oncol. Biol. Phys.

Cellular Radiobiology

Survey of radiosensitivity in a variety of human cell strains

Cancer Res.

The radiation response of human malignant melanoma cells grown in vitro

Cancer Res.

Changes in sensitivity of the HeLa cells after split dose of X-rays

Int. J. Radiat. Biol.

In vitro radiation and chemotherapy sensitivity of established cell lines of human small cell lung cancer and its large cell morphological variants

Cancer Res.

Establishments, characterisation and response to cytotoxic and radiation treatment of three human melanoma cell lines

In vitro

In vitro low dose survival of freshly excised human tumour cells (Abstract)

Ataxia telangiectasia. Evaluation of radiosensitivity in cultured skin fibroblasts as a diagnostic test

Arch. Dis. Child.

Radiosensitivity and repair of radiation damage in human HF19 fibroblasts

Int. J. Radiat. Biol.

Radiation survival of glutathione deficient human fibroblasts in culture

Brit. J. Radiol.

Mean inactivation dose: a useful concept for intercomparison of human cell survival curves

Radiat. Res.

In vitro radiosensitivity of six human cell lines. A comparative study with different statistical models

Radiat. Res.

Radiation sensitivity of cultured human glioblastoma cells

Radiology

Dose rate. Its effect on the survival of HeLa cells irradiated with gamma rays

Radiat. Res.

Primary bioassay of human tumor stem cells

Science

International Commission on Radiation Units and Measurements: Quantitative concepts and dosimetry in radiobiology

ICRU Report

Oncology intelligence
Intrinsic radiosensitivity of human cell lines is correlated with radioresponsiveness of human tumors: Analysis of 101 published survival curves☆